Aspirin and Statin Use and the Risk of Gallbladder Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hundal, R.; Shaffer, E.A. Gallbladder cancer: Epidemiology and outcome. Clin. Epidemiol. 2014, 6, 99–109. [Google Scholar] [CrossRef] [PubMed]
- Van Dyke, A.L.; Shiels, M.S.; Jones, G.S.; Pfeiffer, R.M.; Petrick, J.L.; Beebe-Dimmer, J.L.; Koshiol, J. Biliary tract cancer incidence and trends in the United States by demographic group, 1999–2013. Cancer 2019, 125, 1489–1498. [Google Scholar] [CrossRef] [PubMed]
- Hsing, A.W.; Gao, Y.T.; Han, T.Q.; Rashid, A.; Sakoda, L.C.; Wang, B.S.; Shen, M.C.; Zhang, B.H.; Niwa, S.; Chen, J.; et al. Gallstones and the risk of biliary tract cancer: A population-based study in China. Br. J. Cancer 2007, 97, 1577–1582. [Google Scholar] [CrossRef]
- Henley, S.J.; Weir, H.K.; Jim, M.A.; Watson, M.; Richardson, L.C. Gallbladder Cancer Incidence and Mortality, United States 1999-2011. Cancer Epidemiol. Biomark. Prev. 2015, 24, 1319–1326. [Google Scholar] [CrossRef] [Green Version]
- Mayo, S.C.; Mavros, M.N.; Nathan, H.; Cosgrove, D.; Herman, J.M.; Kamel, I.; Anders, R.A.; Pawlik, T.M. Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma: A National Perspective. J. Am. Coll. Surg. 2014, 218, 196–205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elwood, P.C.; Gallagher, A.M.; Duthie, G.G.; Mur, L.A.; Morgan, G. Aspirin, salicylates, and cancer. Lancet 2009, 373, 1301–1309. [Google Scholar] [CrossRef]
- Choi, J.; Ghoz, H.M.; Peeraphatdit, T.; Baichoo, E.; Addissie, B.D.; Harmsen, W.S.; Therneau, T.M.; Olson, J.E.; Chaiteerakij, R.; Roberts, L.R. Aspirin use and the risk of cholangiocarcinoma. Hepatology 2016, 64, 785–796. [Google Scholar] [CrossRef] [Green Version]
- Gala, M.K.; Chan, A.T. Molecular pathways: Aspirin and Wnt signaling—A molecularly targeted approach to cancer prevention and treatment. Clin. Cancer Res. 2015, 21, 1543–1548. [Google Scholar] [CrossRef] [Green Version]
- Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252–266. [Google Scholar] [CrossRef] [Green Version]
- Liu, E.; Sakoda, L.C.; Gao, Y.T.; Rashid, A.; Shen, M.C.; Wang, B.S.; Deng, J.; Han, T.Q.; Zhang, B.H.; Fraumeni, J.F., Jr.; et al. Aspirin use and risk of biliary tract cancer: A population-based study in Shanghai, China. Cancer Epidemiol. Biomark. Prev. 2005, 14, 1315–1318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gonzalez-Perez, A.; Garcia Rodriguez, L.A.; Lopez-Ridaura, R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis. BMC Cancer 2003, 3, 28. [Google Scholar] [CrossRef] [Green Version]
- McNeil, J.J.; Gibbs, P.; Orchard, S.G.; Lockery, J.E.; Bernstein, W.B.; Cao, Y.; Ford, L.; Haydon, A.; Kirpach, B.; Macrae, F.; et al. Effect of aspirin on cancer incidence and mortality in older adults. J. Natl. Cancer Inst. 2020. [Google Scholar] [CrossRef]
- Asano, T.; Shoda, J.; Ueda, T.; Kawamoto, T.; Todoroki, T.; Shimonishi, M.; Tanabe, T.; Sugimoto, Y.; Ichikawa, A.; Mutoh, M.; et al. Expressions of Cyclooxygenase-2 and Prostaglandin E-Receptors in Carcinoma of the Gallbladder. Clin. Cancer. Res. 2002, 8, 1157–1167. [Google Scholar]
- Bodmer, M.; Brauchli, Y.B.; Krähenbühl, S.; Jick, S.S.; Meier, C.R. Statin use and risk of gallstone disease followed by cholecystectomy. Jama 2009, 302, 2001–2007. [Google Scholar] [CrossRef]
- Erichsen, R.; Frøslev, T.; Lash, T.L.; Pedersen, L.; Sørensen, H.T. Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am. J. Epidemiol. 2011, 173, 162–170. [Google Scholar] [CrossRef]
- Boudreau, D.M.; Yu, O.; Johnson, J. Statin use and cancer risk: A comprehensive review. Expert Opin. Drug Saf. 2010, 9, 603–621. [Google Scholar] [CrossRef] [Green Version]
- Brusselaers, N.; Lagergren, J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open 2018, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goel, A.; Chang, D.K.; Ricciardiello, L.; Gasche, C.; Boland, C.R. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin. Cancer Res. 2003, 9, 383–390. [Google Scholar] [PubMed]
- Din, F.; Dunlop, M.; Stark, L. Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis. Br. J. Cancer 2004, 91, 381. [Google Scholar] [CrossRef] [PubMed]
- Coogan, P.F.; Rosenberg, L.; Palmer, J.R.; Strom, B.L.; Zauber, A.G.; Stolley, P.D.; Shapiro, S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol. Biomark. Prev. 2000, 9, 119–123. [Google Scholar]
- Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 2007, 356, 2131–2142. [Google Scholar] [CrossRef]
- Wang, J.; Cho, N.L.; Zauber, A.G.; Hsu, M.; Dawson, D.; Srivastava, A.; Mitchell-Richards, K.A.; Markowitz, S.D.; Bertagnolli, M.M. Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH. Cancer Epidemiol. Biomark. Prev. 2018, 27, 728–736. [Google Scholar] [CrossRef] [Green Version]
- Han, C.; Wu, T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 2005, 280, 24053–24063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moon, W.S.; Park, H.S.; Lee, H.; Pai, R.; Tarnawski, A.S.; Kim, K.R.; Jang, K.Y. Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res. Treat. 2005, 37, 171–176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yadav, A.; Gupta, A.; Yadav, S.; Rastogi, N.; Agrawal, S.; Kumar, A.; Kumar, V.; Misra, S.; Mittal, B. Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival. Tumor Biol. 2016, 37, 8083–8095. [Google Scholar] [CrossRef] [PubMed]
- Rüschoff, J.; Wallinger, S.; Dietmaier, W.; Bocker, T.; Brockhoff, G.; Hofstädter, F.; Fishel, R. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc. Natl. Acad. Sci. USA 1998, 95, 11301–11306. [Google Scholar] [CrossRef] [Green Version]
- Liu, Z.; Alsaggaf, R.; McGlynn, K.A.; Anderson, L.A.; Tsai, H.T.; Zhu, B.; Zhu, Y.; Mbulaiteye, S.M.; Gadalla, S.M.; Koshiol, J. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut 2019, 68, 1458–1464. [Google Scholar] [CrossRef]
- Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature 1990, 343, 425. [Google Scholar] [CrossRef]
- Agarwal, B.; Bhendwal, S.; Halmos, B.; Moss, S.F.; Ramey, W.G.; Holt, P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res. 1999, 5, 2223–2229. [Google Scholar]
- Cafforio, P.; Dammacco, F.; Gernone, A.; Silvestris, F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005, 26, 883–891. [Google Scholar] [CrossRef] [Green Version]
- Marcelli, M.; Cunningham, G.R.; Haidacher, S.J.; Padayatty, S.J.; Sturgis, L.; Kagan, C.; Denner, L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 1998, 58, 76–83. [Google Scholar]
- Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286, 64–70. [Google Scholar] [CrossRef] [PubMed]
- Rezaie-Majd, A.; Maca, T.; Bucek, R.A.; Valent, P.; Müller, M.R.; Husslein, P.; Kashanipour, A.; Minar, E.; Baghestanian, M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 1194–1199. [Google Scholar] [CrossRef] [PubMed]
- Garber, A.J.; Handelsman, Y.; Grunberger, G.; Einhorn, D.; Abrahamson, M.J.; Barzilay, J.I.; Blonde, L.; Bush, M.A.; DeFronzo, R.A.; Garber, J.R.; et al. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm—2020 Executive Summary. Endocr. Pract. 2020, 26, 107–139. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.; Sng, W.K.; Quah, J.H.; Liu, J.; Chong, B.Y.; Lee, H.K.; Wang, X.F.; Tan, N.C.; Chang, P.E.; Tan, H.C.; et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS ONE 2020, 15, e0236977. [Google Scholar] [CrossRef] [PubMed]
- Shaffer, E.A. Gallbladder cancer: The basics. Gastroenterol Hepatol. 2008, 4, 737–741. [Google Scholar]
- Tazuma, S.; Kajiyama, G.; Mizuno, T.; Yamashita, G.; Miura, H.; Kajihara, T.; Hattori, Y.; Miyake, H.; Nishioka, T.; Hyogo, H.; et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J. Clin. Gastroenterol. 1998, 26, 287–291. [Google Scholar] [CrossRef]
- Rahman, R.; Simoes, E.J.; Schmaltz, C.; Jackson, C.S.; Ibdah, J.A. Trend analysis and survival of primary gallbladder cancer in the United States: A 1973–2009 population-based study. Cancer Med. 2017, 6, 874–880. [Google Scholar] [CrossRef] [PubMed]
- Mahipal, A.; Anderson, K.E.; Limburg, P.J.; Folsom, A.R. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women’s health study. Cancer Epidemiol. Prev. Biomark. 2006, 15, 1785–1790. [Google Scholar] [CrossRef] [Green Version]
Characteristics | Cases (N = 795) | Controls (N = 1590) |
---|---|---|
Age, Median | 67 | 67.5 |
Female Sex | 514 (64.7%) | 1028 (64.7%) |
Male Sex | 281 (35.3%) | 562 (35.3%) |
Year of Diagnosis | ||
2000–2004 | 174 (21.9%) | 0 (0.0%) |
2005–2009 | 217 (27.3%) | 115 (7.2%) |
2010–2014 | 192 (24.2%) | 1212 (76.2%) |
2015+ | 212 (26.7%) | 263 (16.5%) |
BMI, Median (IQR) | 27.5 (24.2, 31.9) | 29.9 (26.4, 35.0) |
Cholelithiasis | 383 (48.4%) | 0 (0.0%) |
Cholecystitis | 88 (11.1%) | 110 (6.9%) |
Diabetes | 149 (18.8%) | 422 (26.5%) |
Hypercholesterolemia | 236 (29.8%) | 923 (58.6%) |
Hypertension | 360 (45.4%) | 1000 (65.0%) |
Hyperthyroidism | 6 (0.8%) | 6 (0.4%) |
Hypothyroidism | 110 (13.9%) | 364 (22.9%) |
PSC | 28 (3.5%) | 9 (0.6%) |
IBD | 42 (5.3%) | 42 (2.6%) |
Cirrhosis | 20 (2.5%) | 32 (2.0%) |
Smoking | ||
No | 538 (67.87%) | 1247 (78.4%) |
Yes | 153 (19.2%) | 343 (21.6%) |
Missing | 104 (13.1%) | 0 (0.0%) |
Alcohol Abuse | ||
No | 525 (66.0%) | 496 (31.2%) |
Yes | 23 (2.9%) | 1094 (68.8%) |
Missing | 247 (31.1%) | 0 (0.0%) |
Statin | ||
Missing | 37 | 0 |
No | 602 (79.4%) | 1059 (66.6%) |
Yes | 156 (20.6%) | 531 (33.4%) |
Aspirin | ||
Missing | 33 | 3 |
No | 567 (74.4%) | 573 (36.1%) |
Yes | 195 (25.6%) | 1014 (63.9%) |
Statin/Aspirin | ||
Missing | 39 | 3 |
Neither | 493 (65.2%) | 382 (24.1%) |
Statin Only | 74 (9.8%) | 191 (12.0%) |
Aspirin Only | 107 (14.2%) | 675 (42.5%) |
Both Statin and Aspirin | 82 (10.8%) | 339 (21.4%) |
Characteristics | Odds Ratio (95% CI) | p-Value |
---|---|---|
BMI (per 1 kg/m2) | 0.94 (0.92–0.95) | <0.001 |
Cholecystitis (Yes vs. No) | 1.71 (1.26–2.30) | <0.001 |
Diabetes (Yes vs. No) | 0.53 (0.41–0.68) | <0.001 |
Hypercholesterolemia (Yes vs. No) | 0.30 (0.25–0.36) | <0.001 |
Hypertension (Yes vs. No) | 0.44 (0.37–0.53) | <0.001 |
Hyperthyroidism (Yes vs. No) | 2.00 (0.65–6.20) | 0.23 |
Hypothyroidism (Yes vs. No) | 0.52 (0.41–0.66) | <0.001 |
PSC (Yes vs. No) | 6.22 (2.94–13.19) | <0.001 |
IBD (Yes vs. No) | 2.06 (1.33–3.20) | 0.001 |
Cirrhosis (Yes vs. No) | 1.26 (0.71–2.23) | 0.42 |
Smoking (Yes vs. No) | 1.04 (0.84–1.30) | 0.71 |
Alcohol abuse (Yes vs. No) | 0.02 (0.01–0.04) | <0.001 |
Statin (Yes vs. No) | 0.53 (0.43–0.65) | <0.001 |
Aspirin (Yes vs. No) | 0.18 (0.15–0.23) | <0.001 |
Statin/Aspirin | ||
Neither | Reference | |
Statin Only | 0.29 (0.20–0.40) | <0.001 |
Aspirin Only | 0.11 (0.08–0.15) | <0.001 |
Both Statin and Aspirin | 0.18 (0.13–0.24) | <0.001 |
Characteristics | Overall | Male | Female | |||
---|---|---|---|---|---|---|
Odds Ratio (95%CI) | p-Value | Odds Ratio (95%CI) | p-Value | Odds Ratio (95%CI) | p-Value | |
Diabetes | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.73 (0.55–0.98) | 0.033 | 0.79 (0.49–1.27) | 0.32 | 0.71 (0.49–1.02) | 0.067 |
Hypercholesterolemia | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.31 (0.23–0.42) | <0.001 | 0.42 (0.26–0.69) | < 0.001 | 0.27 (0.18–0.39) | <0.001 |
Hypertension | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.75 (0.60–0.95) | 0.015 | 0.95 (0.65–1.38) | 0.78 | 0.64 (0.48–0.87) | 0.004 |
Hypothyroidism | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.53 (0.39–0.71) | <0.001 | 0.55 (0.28–1.07) | 0.078 | 0.52 (0.37–0.73) | <0.001 |
PSC | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 5.84 (1.91–17.89) | 0.002 | 6.54 (1.26–34.03) | 0.026 | 5.71 (1.06–30.87) | 0.043 |
IBD | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 1.01 (0.55–1.86) | 0.98 | 1.57 (0.65–3.76) | 0.31 | 0.71 (0.28–1.76) | 0.46 |
Cirrhosis | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.83 (0.37–1.87) | 0.65 | 2.96 (0.71–12.32) | 0.13 | 0.41 (0.13–1.30) | 0.13 |
Statin/ASA | ||||||
Neither | Reference | - | Reference | - | Reference | - |
Statin Only | 0.76 (0.50–1.15) | 0.19 | 1.03 (0.49–2.19) | 0.93 | 0.67 (0.40–1.12) | 0.13 |
ASA Only | 0.12 (0.09–0.16) | <0.001 | 0.14 (0.09–0.22) | <0.001 | 0.11 (0.08–0.17) | <0.001 |
Both Statin and ASA | 0.46 (0.31–0.67) | <0.001 | 0.56 (0.31–1.01) | 0.053 | 0.38 (0.23–0.63) | <0.001 |
Characteristics | Odds Ratio (95%CI) | p-Value |
---|---|---|
BMI (per 1 kg/m2) | 0.94 (0.92–0.95) | <0.001 |
Cholecystitis (Yes vs. No) | 1.74 (1.26–2.41) | <0.001 |
Diabetes (Yes vs. No) | 0.59 (0.45–0.76) | <0.001 |
Hypercholesterolemia (Yes vs. No) | 0.31 (0.26–0.38) | <0.001 |
Hypertension (Yes vs. No) | 0.49 (0.40–0.59) | <0.001 |
Cirrhosis (Yes vs. No) | 0.77 (0.37–1.60) | 0.48 |
Smoking (Yes vs. No) | 1.16 (0.91–1.46) | 0.23 |
Alcohol abuse (Yes vs. No) | 0.02 (0.01, 0.03) | <0.001 |
Statin (Yes vs. No) | 0.56 (0.45–0.69) | <0.001 |
Aspirin (Yes vs. No) | 0.17 (0.14–0.22) | <0.001 |
Statin/Aspirin | - | - |
Neither | Reference | - |
Statin Only | 0.31 (0.22–0.44) | <0.001 |
Aspirin Only | 0.10 (0.08–0.14) | <0.001 |
Both Statin and Aspirin | 0.17 (0.13–0.24) | <0.001 |
Characteristics | Overall | Male | Female | |||
---|---|---|---|---|---|---|
Odds Ratio (95%CI) | p-Value | Odds Ratio (95%CI) | p-Value | Odds Ratio (95%CI) | p-Value | |
Diabetes | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.79 (0.58–1.07) | 0.13 | 0.78 (0.47–1.30) | 0.34 | 0.79 (0.54–1.17) | 0.24 |
Hypercholesterolemia | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.30 (0.22–0.42) | <0.001 | 0.42 (0.24–0.70) | 0.001 | 0.26 (0.17–0.38) | <0.001 |
Hypertension | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.85 (0.67–1.08) | 0.18 | 1.09 (0.73–1.62) | 0.68 | 0.73 (0.53–0.99) | 0.046 |
Cirrhosis | ||||||
No | Reference | - | Reference | - | Reference | - |
Yes | 0.81 (0.33–1.98) | 0.64 | 2.52 (0.59–10.79) | 0.21 | 0.39 (0.10–1.42) | 0.15 |
Statin/ASA | ||||||
Neither | Reference | - | Reference | - | Reference | - |
Statin Only | 0.77 (0.50–1.19) | 0.24 | 1.00 (0.45–2.24) | 0.99 | 0.69 (0.40–1.17) | 0.17 |
ASA Only | 0.11 (0.08–0.15) | <0.001 | 0.13 (0.08–0.21) | <0.001 | 0.10 (0.06–0.14) | <0.001 |
Both Statin and ASA | 0.42 (0.28–0.63) | <0.001 | 0.55 (0.30–1.02) | 0.056 | 0.33 (0.19–0.57) | <0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Prasai, K.; Tella, S.H.; Yadav, S.; Kommalapati, A.; Mara, K.; Mady, M.; Hassan, M.A.; Wongjarupong, N.; Rodriguez-Payan, N.; Borad, M.; et al. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers 2021, 13, 1186. https://doi.org/10.3390/cancers13051186
Prasai K, Tella SH, Yadav S, Kommalapati A, Mara K, Mady M, Hassan MA, Wongjarupong N, Rodriguez-Payan N, Borad M, et al. Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers. 2021; 13(5):1186. https://doi.org/10.3390/cancers13051186
Chicago/Turabian StylePrasai, Kritika, Sri Harsha Tella, Siddhartha Yadav, Anuhya Kommalapati, Kristin Mara, Mohamed Mady, Mohamed A. Hassan, Nicha Wongjarupong, Natalia Rodriguez-Payan, Mitesh Borad, and et al. 2021. "Aspirin and Statin Use and the Risk of Gallbladder Cancer" Cancers 13, no. 5: 1186. https://doi.org/10.3390/cancers13051186